Short-term efficacy and adverse reactions of gemcitabine plus cis-platinum chemotherapy in moderate and advanced non-small cell lung cancer with silicosis
Pang Bo
Dong Mingxia
Li Juan
Qiu Zuwen
Hu Gaolin
Li Xi
Hu Zhuojun
Xu Jun
Abstract：Objective To observe the short-term effect and adverse reaction of gemcitabine plus cis-platinum chemotherapy in the treatment of patients with moderate and advanced non-small cell lung cancer (NSCLC) and silicosis.Methods A total of 65 NSCLC patients with silicosis were enrolled from January 2012 to June 2017 in the Second People's Hospital of Panzhihua.The patients were randomly assigned to control group(n =32) and observation group(n =33).The control group was treated with gefitinib plus cis-platinum chemotherapy and the observation group was treated with gemcitabine plus cis-platinum chemotherapy.Short-term efficacy,symptomatic remission and adverse reactions were analyzed.Results Short-term effective rate was equal between observation group and control group[87.9％ (29/33) vs 84.4％ (27/32)] (P =0.683).Objective remission rate in observation group was significantly higher than that in control group[69.7％ (23/33) vs 43.8％ (14/32)] (P =0.035).Symptom response time of hemoptysis,irritable cough,expiratory dyspnea,chest pain and tightness in observation group were significantly shorter than those in control group [(4.3 ± 0.3) d vs (6.9 ± 1.3) d,(5.0 ± 0.6) d vs (11.6±0.9)d,(5.0±2.0)dvs (8.0±1.2)d,(7.0±1.6)dvs (10.4±1.2)d](P＜0.01).Most patients had adverse reactions of stage Ⅰ / Ⅱ.Incidences of leukopenia and thrombocytopenia in observation group were significantly lower than those in control group (P ＜ 0.05).Conclusion Gemcitabine plus cis-platinum can remarkably increase the short-term effect and relieve clinical symptoms,produces no serious adverse reaction and shows good safety in the treatment of moderate and advanced NSCLC with silicosis.
Keywords：Non-small cell lung cancerSilicosisGemcitabineGefitinibCis-platinum
Publication Date：2019-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 522-525 )